scholarly journals Significant increases in serum and plasma concentrations of matrix metalloproteinases 3 and 9 in patients with rapidly destructive osteoarthritis of the hip

2002 ◽  
Vol 46 (10) ◽  
pp. 2625-2631 ◽  
Author(s):  
Kensaku Masuhara ◽  
Tsuyoshi Nakai ◽  
Katsuyuki Yamaguchi ◽  
Satoshi Yamasaki ◽  
Yasuyuki Sasaguri
Keyword(s):  
Matrix Metalloproteinases ◽  
Plasma Concentrations ◽  
Osteoarthritis Of The Hip ◽  
Destructive Osteoarthritis

Rapidly Destructive Osteoarthritis of the Hip: MR Imaging Findings

2002 ◽  
Vol 179 (3) ◽  
pp. 657-663 ◽  
Author(s):  
Nathalie Boutry ◽  
Christelle Paul ◽  
Xavier Leroy ◽  
David Fredoux ◽  
Henri Migaud ◽  
...  
Keyword(s):  
Mr Imaging ◽  
Imaging Findings ◽  
Osteoarthritis Of The Hip ◽  
Destructive Osteoarthritis

Rapidly destructive osteoarthritis of the hip: Case presentation

2011 ◽  
Vol 7 (1) ◽  
pp. 56-58
Author(s):  
Elvis Junior Amao Ruiz ◽  
Manuel Raimundo Bayón Calatayud ◽  
José Antonio Nieto Rodríguez ◽  
Eva García Alberdi
Keyword(s):  
Osteoarthritis Of The Hip ◽  
Case Presentation ◽  
Destructive Osteoarthritis

scholarly journals Matrix Metalloproteinases MMP-2 and MMP-9 Occupy a New Role in Severe Preeclampsia

2020 ◽  
Vol 2020 ◽  
pp. 1-7
Author(s):  
Elena Timokhina ◽  
Alexander Strizhakov ◽  
Sapiyat Ibragimova ◽  
Evgeny Gitel ◽  
Irina Ignatko ◽  
...  
Keyword(s):  
Matrix Metalloproteinases ◽  
Pregnant Women ◽  
Blood Vessels ◽  
Late Onset ◽  
Plasma Concentrations ◽  
Normal Pregnancy ◽  
Severe Preeclampsia ◽  
Control Group ◽  
Threatening Condition ◽  
Early Onset Preeclampsia

Introduction. Preeclampsia (PE) is a life-threatening condition for the mother, the fetus, and the newborn. Matrix metalloproteinases (MMP) participate in the two primary stages of PE: remodeling of blood vessels at the stage of placental formation and the development of hypertension due to damage to the basement membrane of blood vessels. The object of the present study was to reveal the role of MMP-2 and MMP-9 in the development of severe preeclampsia. Materials and Methods. We conducted a retrospective study that included 92 pregnant women at a gestational age of 26-38 weeks, of which the principal group consisted of 61 patients with severe PE. We divided the principal group into two subgroups: the first subgroup was designated the severe early-onset preeclampsia (EO-PE) group and consisted of 30 pregnant women. The second group was designated the severe late-onset preeclampsia (LO-PE) group, comprising 31 patients. We determined the plasma concentrations of MMPs 2 and 9 in the groups with an ELISA. Results. In the group of PE patients with both EO-PE and LO-PE, the level of MMP-2 was significantly higher compared to the women undergoing normal pregnancy; and we observed no significant differences when we compared the levels of MMP-2 in the subgroups with EO-PE and LO-PE. Analysis of the concentrations of MMP-9 in EO-PE and LO-PE subgroups revealed attenuated levels of MMP-9 in both groups relative to the control group. We also noted a diminished level of MMP-9 in the EO-PE group compared to the LO-PE group. Conclusions. The significantly increased levels of MMP-2 in women—both in the EO-PE and LO severe PE subgroups—explain the participation of this enzyme in endothelial dysfunction in the second stage of severe PE. A diminution in MMP-9 in the EO-PE group confirmed the participation of MMP-9 in the process of spiral artery transformation.

Variations with time of plasma concentrations of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2

2007 ◽  
Vol 119 (2) ◽  
pp. 261-263 ◽  
Author(s):  
Patrick Rossignol ◽  
Michèle Cambillau ◽  
Dikran Mouradian ◽  
Pierre-François Plouin ◽  
Gilles Chatellier ◽  
...  
Keyword(s):  
Matrix Metalloproteinases ◽  
Plasma Concentrations ◽  
Tissue Inhibitors Of Metalloproteinases ◽  
Tissue Inhibitors

scholarly journals Matrix metalloproteinases in patients with osteoarthritis of the hip

2000 ◽  
Vol 24 (2) ◽  
pp. 92-96 ◽  
Author(s):  
K. Masuhara ◽  
S. Bak Lee ◽  
T. Nakai ◽  
N. Sugano ◽  
T. Ochi ◽  
...  
Keyword(s):  
Matrix Metalloproteinases ◽  
Osteoarthritis Of The Hip

scholarly journals A case of rapidly destructive osteoarthritis of the hip with onset of less than six weeks

2017 ◽  
Vol 8 ◽  
pp. S72-S75
Author(s):  
Elina Huerfano ◽  
Maria Bautista ◽  
Guillermo Bonilla ◽  
Mauricio Palau-Lazaro ◽  
Adolfo Llinás ◽  
...  
Keyword(s):  
Osteoarthritis Of The Hip ◽  
Destructive Osteoarthritis

scholarly journals Total Hip Arthroplasty in Rapidly Destructive Osteoarthritis of the Hip: A Case Series

2009 ◽  
Vol 5 (2) ◽  
pp. 117-119 ◽  
Author(s):  
Alfred Kuo ◽  
Kace A. Ezzet ◽  
Shantanu Patil ◽  
Clifford W. Colwell
Keyword(s):  
Total Hip Arthroplasty ◽  
Hip Arthroplasty ◽  
Case Series ◽  
Osteoarthritis Of The Hip ◽  
Total Hip ◽  
Destructive Osteoarthritis

Increased Levels and Activities of Matrix Metalloproteinases in Sickle Cell Disease.

Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 1220-1220
Author(s):  
Carla F. Franco-Penteado ◽  
Stephen Hyslop ◽  
Nicola Conran ◽  
Sara T.O. Saad ◽  
Fernando F. Costa
Keyword(s):  
Sickle Cell Disease ◽  
Matrix Metalloproteinases ◽  
Sickle Cell ◽  
Plasma Concentrations ◽  
Gelatin Zymography ◽  
Control Group ◽  
Cell Disease ◽  
Cell Counts ◽  
Significant Difference ◽  
Leukocyte Counts

Abstract Sickle cell disease is characterized by a chronic inflammatory state, however, the mechanism underlying this inflammation is unclear. Elevated basal leukocyte counts, endothelial activation, altered availability of vaso-active factors, increased adhesion molecule expression and cytokines are found in this disease. Matrix metalloproteinases (MMPs) play an important role in physiological and pathological processes, participating in the extracellular matrix turnover as well as tissue degradation, repair mechanisms and cell migration. Since MMPs are important modulators of inflammation and the activity of cytokines and chemokines, our aim was to compare MMP and tissue inhibitor of matrix metalloproteinases (TIMP; inhibitors of MMP) levels and the activities of MMPs in the plasma of healthy subjects and in SCD patients on or off HU therapy (20–30 mg/kg/day, 3 month minimum duration). Gelatin zymography was used to measure MMP-2 and MMP-9 activities and ELISA was used for MMPs and TIMPs determination. After densitometric analysis of zymograms, a significant increase (p=0.03) in the activity of pro-MMP-9 was observed in the plasma of SCD patients (27.09 ± 1.99 average pixel, n=30) compared with the control group (20.96 ± 1.35 average pixel, n=29). Pro-MMP-9 activity in the plasma of SCD patients on HU (SCDHU) was greater (27.2 ± 1.35 average pixel, n=17); however this difference was not quite significant (p=0.07). With regard to MMP-2 activity, no significant difference (P>0.05, data not shown) between groups of patients and control individuals was observed. MMP-9 levels were significantly increased in the plasma of SCD patients (20.99 ± 1.52, n=32) compared to healthy controls (13.96 ± 1.64, n=16, p=0.02), although no effect of HU therapy on these augmented levels was observed (SCDHU; 23.66 ± 2.93, n=22, P>0.05). MMP-9 levels correlated significantly with total WBC counts (r=0.4221, p=0.01) in SCD patients (on and off HU), as well as with neutrophil counts (r=0.4436, p<0.001), but not with mononuclear cell counts. TIMP-1 and TIMP-2 levels were significantly (p<0.0001) higher in SCD patients not on HU therapy (83.69 ± 6.73, n=15; 95.49 ± 4.99, n=14, respectively) compared to control individuals (41.26 ± 3.75, n=11; 62.84 ± 3.43, n=10, respectively). HU therapy had no significant effect on increased TIMP-1 levels (84.14 ± 4.69, n=12, p>0.05) when compared to SCD patients not on HU. TIMP-2 levels were higher in SCD patients treated with HU (87.62 ± 9.39, n=12) than those observed in control subjects, however this difference was not quite significant (p=0.059). In contrast, MMP-2 and MMP-8 plasma concentrations were not significantly different in SCD individuals compared to controls (P>0.05). Data demonstrate, for the first time, that the level and activity of plasma MMP-9 are significantly increased in SCD, and that these levels are not affected by HU therapy. Importantly, MMP-9 levels correlate with leukocyte counts in SCD, indicating that MMP-9 may be a useful marker for inflammation in SCD.

Sign in / Sign up

Export Citation Format

Share Document